{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:33Z","timestamp":1792440633051,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study utilizes data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) to conduct a post-marketing safety evaluation of Tofersen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of the FAERS database was performed to identify adverse event (AE) reports from Q1 2023 to Q4 2025 was performed. Multi-dimensional disproportionality analyses were conducted using the ROR, PRR, BCPNN, and MGPS method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 409 Tofersen-related reports were identified, revealing significant signals across 22 System Organ Class (SOC) categories and 369 Preferred Terms (PTs). At the SOC level, the most prominent safety signals were observed in injury, poisoning and procedural complications, nervous system disorders, and musculoskeletal and connective tissue disorders. In contrast, ear and labyrinth disorders, as well as respiratory, thoracic and mediastinal disorders, were not listed in the current product labeling and may warrant further investigation. At the PT level, neurological procedural complication, CSF red blood cell count positive, CSF white blood cell count increased, and CSF cell count increased exhibited the strongest signals, primarily reflecting cerebrospinal fluid cytological and biochemical abnormalities, as well as procedural-related adverse events such as post-lumbar puncture syndrome, procedural pain, and procedural headache. Although central nervous system-related events (e.g., increased intracranial pressure, peroneal nerve palsy, papilloedema, and facial paralysis) and infectious or inflammatory events (e.g., radiculopathy, myelitis, aspiration pneumonia, and meningitis) were less frequently reported, their relatively high disproportionality signals warrant clinical attention and systematic monitoring. Notably, a newly identified signal of pulmonary embolism suggests a potential thromboembolic risk in specific patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide real-world evidence to inform the balance between the therapeutic potential and safety profile of Tofersen. Future clinical strategies should focus on mitigating central nervous system-related and procedure-related adverse events. Further mechanistic studies are crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1843630","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:58:30Z","timestamp":1779425910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety evaluation of Tofersen in amyotrophic lateral sclerosis based on the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuefeng","family":"Xiao","sequence":"first","affiliation":[{"name":"Suzhou Polytechnic University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Hao","sequence":"additional","affiliation":[{"name":"Suzhou Polytechnic University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wan","sequence":"additional","affiliation":[{"name":"Affiliated Mental Health Center of Jiangnan University","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuang","family":"Hou","sequence":"additional","affiliation":[{"name":"Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People\u2019s Hospital","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10654-015-0090-x","article-title":"Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin","volume":"31","author":"Marin","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/ije\/dyw061","article-title":"Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis","volume":"46","author":"Marin","year":"2017","journal-title":"Int J Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref7","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1006-15","DOI":"10.1002\/mus.28372","article-title":"Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis","volume":"71","author":"Lovett","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"key":"ref10","year":"2024"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1054006","DOI":"10.3389\/fphar.2022.1054006","article-title":"New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jad.2025.03.007","article-title":"Post-marketing safety evaluation of Vortioxetine: a decade-long pharmacovigilance study based on the FAERS database","volume":"379","author":"Wu","year":"2025","journal-title":"J Affect Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/s0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/17482960802430781","article-title":"Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain","volume":"10","author":"L\u00f3pez-Bastida","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1038\/ncomms12408","article-title":"Projected increase in amyotrophic lateral sclerosis from 2015 to 2040","volume":"7","author":"Arthur","year":"2016","journal-title":"Nat Commun"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/21678421.2017.1364269","article-title":"Writing Group on Behalf of the Edaravone (MCI-186) ALS 19 Study Group. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.arr.2024.102228","article-title":"Sex biology in amyotrophic lateral sclerosis","volume":"95","author":"Zamani","year":"2024","journal-title":"Ageing Res Rev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mus.27942","article-title":"Exposure to endogenous and exogenous sex hormones and reproductive history influence prognosis in women with ALS","volume":"68","author":"Gonzalez Deniselle","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5582\/ddt.2024.01090","article-title":"Characteristics and patterns of adverse event reports in the Japanese adverse drug event report database over two decades (2004-2023): exploring findings on sexes and age groups","volume":"19","author":"Tanaka","year":"2025","journal-title":"Drug Discov Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/bf03261977","article-title":"Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review","volume":"35","author":"Inch","year":"2012","journal-title":"Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States Food and Drug Administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of Bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/nat.2020.0867","article-title":"Immunogenicity assessment of Inotersen, a 2'-O-(2-Methoxyethyl) antisense oligonucleotide in animals and humans: effect on pharmacokinetics, pharmacodynamics, and safety","volume":"30","author":"Yu","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with Esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother Psychosom"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"Cd013577","DOI":"10.1002\/14651858.Cd013577","article-title":"Epidural corticosteroid injections for lumbosacral radicular pain","volume":"4","author":"Oliveira","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/000456329603300307","article-title":"Inhibition by sodium thiophosphate and L-p-bromotetramisole of neutrophil alkaline phosphatase in normal and trisomy 21 pregnancies","volume":"33","author":"Denier","year":"1996","journal-title":"Ann Clin Biochem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00234-023-03207-9","article-title":"Association between resistance to cerebrospinal fluid flow and cardiac-induced brain tissue motion for Chiari malformation type I","volume":"65","author":"Mohsenian","year":"2023","journal-title":"Neuroradiology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/14737175.2020.1770084","article-title":"Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments","volume":"20","author":"Krymchantowski","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"17138","DOI":"10.1038\/s41598-024-67627-0","article-title":"Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.mcna.2014.04.001","article-title":"Cervical radiculopathy","volume":"98","author":"Corey","year":"2014","journal-title":"Med Clin North Am"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with SOD1-ALS in a \"real-world\" setting - a 12-month multicenter cohort study from the German early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinMed"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2012.03.008","article-title":"Immune-mediated myelitis following hepatitis B vaccination","volume":"12","author":"St\u00fcbgen","year":"2012","journal-title":"Autoimmun Rev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"V01240062","DOI":"10.61409\/v01240062","article-title":"P. aeruginosa infection of the ulna, a rare complication after arterial puncture","volume":"186","author":"Bomark","year":"2024","journal-title":"Ugeskr Laeger"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.1981.03310390056023","article-title":"Lumbar puncture-induced meningitis","volume":"245","author":"Eng","year":"1981","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2174\/092986710791163957","article-title":"Recognition of nucleic acids by toll-like receptors and development of immunomodulatory drugs","volume":"17","author":"Kuznik","year":"2010","journal-title":"Curr Med Chem"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"8107","DOI":"10.1093\/nar\/gkac618","article-title":"Insights into innate immune activation via PS-ASO-protein-TLR9 interactions","volume":"50","author":"Pollak","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"884277","DOI":"10.3389\/fpain.2022.884277","article-title":"Pressure-volume relationships in the spinal canal and potential neurological complications after epidural fluid injections","volume":"3","author":"Bosscher","year":"2022","journal-title":"Front Pain Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3233\/jnd-230032","article-title":"Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen","volume":"10","author":"Machetanz","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/s0140-6736(04)16004-2","article-title":"Pulmonary embolism","volume":"17","author":"Goldhaber","year":"2004","journal-title":"Lancet (London, England)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.clineuro.2004.05.002","article-title":"Thrombosis and thrombophilebitis of the internal jugular vein as a very rare complication of the ventriculoatrial shunt","volume":"107","author":"Yurtseven","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/BF01959083","article-title":"Pulmonary hypertension complicating a ventriculo-atrial shunt","volume":"151","author":"Haasnoot","year":"1992","journal-title":"Eur J Pediatr"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/ijms26083532","article-title":"Breaking the barrier: the role of proinflammatory cytokines in BBB dysfunction","volume":"26","author":"Gryka-Marton","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/aite-2024-0003","article-title":"Acute pulmonary embolism and immunity in animal models","volume":"72","author":"Imiela","year":"2024","journal-title":"Arch Immunol Ther Exp"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/0002-9149(84)90271-6","article-title":"Infection and right atrial pseudotumor complicating a verrtriculoatrial shunt for hydrocephalus","volume":"54","author":"Iqbal","year":"1984","journal-title":"Am J Cardiol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1843630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:58:33Z","timestamp":1779425913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1843630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":48,"alternative-id":["10.3389\/fneur.2026.1843630"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1843630","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1843630"}}